Please assess the completion status of the following clinical trial:

Trial Title: Renal Sympathetic Denervation by Iberis System in Patients With Uncontrolled Hypertension - Iberis-HTN Registry

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years or minimum age as required by local regulations.~* Patient has been thoroughly informed about this registry and signed Informed Consent Form.~* Patient with true resistant hypertension defined as:~  * Office systolic BP higher than 160 or 150mmHg in case of type 2 diabetes~ * Ambulatory BP with average BP\>130mmHg or mean daytime\>135mmHg in more than 70% of the measurements.~* Patients should be on stable hypertension therapy for at least 8 weeks before procedure, including spironolactone if they are supposed to be respondent as indicated by the specialized center/excellence unit on hypertension.~Exclusion Criteria:~* Previous renal artery intervention (balloon angioplasty or stenting).~* Evidence of renal artery atherosclerosis (defined as a renal artery stenosis \>50%).~* Main renal arteries of less than 4mm diameter or less than 20mm in length.~* Presence of multiple main renal arteries in either kidney.~* Estimated glomerular filtration rate \<45ml/min per 1,73m2~* Recent myocardial infarction, unstable angina pectoris or cerebrovascular accident within the past 3-6 months.~* False resistant hypertension (pseudo resistance) by using 24h ambulatory BP monitoring (ABPM).~* Secondary arterial hypertension.~* Pregnancy.~* There is another pathological process with well-known life expectancy of less than 5 years.~* Patient unable to do correct FU.~* Unable to take correct ambulatory BP.~* Primary hyperaldosteronism.~* Known lack of adherence to medical treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).